Comparison
While Retatrutide is an investigational agent that produces very large body-weight reductions in early trials by simultaneously engaging GLP-1R, GIPR, and GCGR to enhance satiety, energy expenditure, and glycemic control2575, Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480.
While Retatrutide works as a triple incretin agonist peptide derived from a GIP backbone and engineered to activate GLP-1, GIP, and glucagon receptors, with non-natural residues and fatty-acid conjugation that confer long half-life and balanced multi-receptor signaling256575, Semaglutide is a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480.
Retatrutide is 39 amino acids long, whereas Semaglutide is shorter as it has a length of 31 amino acids. Retatrutide is made up of a sequence of sequence data not available in the current dataset. Semaglutide is made up of a sequence of sequence data not available in the current dataset.
Retatrutide
Not assigned in the current dataset.
Semaglutide
GCG